Antonino Romeo, MD
IRCCS IRST · IRST IRCCS, Meldola
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Antonino Romeo, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:56 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05861336 · GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic CancerIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · withdrawn · Pancreatic Cancer · principal investigator
- Ph2NCT02035072 · Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer.Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · completed · Unresectable Pancreatic Cancer, Nonmetastatic Pancreatic Cancer, Locally Advanced Pancreatic Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:56 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in pancreatic cancer.